CA2485424A1 - Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use - Google Patents
Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use Download PDFInfo
- Publication number
- CA2485424A1 CA2485424A1 CA002485424A CA2485424A CA2485424A1 CA 2485424 A1 CA2485424 A1 CA 2485424A1 CA 002485424 A CA002485424 A CA 002485424A CA 2485424 A CA2485424 A CA 2485424A CA 2485424 A1 CA2485424 A1 CA 2485424A1
- Authority
- CA
- Canada
- Prior art keywords
- cr13r14
- och2ch2
- carbon atoms
- alkyl
- conr12
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
A cytotoxic agent comprising one or more polyethylene glycol-containing taxanes linked to a cell binding agent. A therapeutic composition for killin g selected cell populations comprising: (A) a cytotoxic amount of one or more polyethylene glycol-containing taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier , diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more polyethylene glycol-containing taxanes linked to a cell binding agent.
Claims (50)
1. A taxane comprising a polyethylene glycol-containing linking group at C-7 or C-10.
2. The taxane of claim 1, wherein the polyethylene glycol-containing linking group comprises a thiol or disulfide as a linking moiety.
3. The taxane of claim 2, wherein the polyethylene glycol-containing linking group is carried on a side chain that is a linear or branched, aromatic or heterocyclic group.
4. The taxane of claim 1, wherein the polyethylene glycol-containing linking group is cleavable.
5. The taxane of claim 1, wherein the polyethylene glycol-containing linking group is acid labile, photolabile, peptidase labile, or esterase labile.
6. The taxane of claim 1, wherein the polyethylene glycol-containing linking group is not cleavable.
7. The taxane of claim 1, wherein the substituent comprising the polyethylene glycol-containing linking group is selected from the group consisting of:
-(CR13R14)l(CH2)m(C R13R14)l(OCH2CH2)nO(C R13R14)l(CH2)m(C R13R14)lSZ, -CO(C R13R14)l(CH2)m(C R13R14)l (OCH2CH2)nO(C R13R14)l(CH2)m(C R13R14)l SZ, -CONR12(C R13R14)l(CH2)m(C R13R14)l(OCH2CH2)nO(C R13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)lSZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)lSZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)lSZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)nOCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)nNR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)nOCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)nOCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)nNR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)t(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO-morpholino-X(OCH2CH2)n SZ, -CO-piperazino-X(OCH2CH2)n SZ, -CO-piperidino-X(OCH2CH2)n SZ, and -CO-N-methylpiperazino-X(OCH2CH2)n SZ, wherein Z is H or SR, X is a linear alkyl or branched alkyl having 1-10 carbon atoms, R and R12 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms or heterocyclic, and R12 can in addition be H, R13 and R14 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or aryl, l is 0 or an integer from 1 to 10, m is an integer of 1 to 10, and n is 2 to 1000.
-(CR13R14)l(CH2)m(C R13R14)l(OCH2CH2)nO(C R13R14)l(CH2)m(C R13R14)lSZ, -CO(C R13R14)l(CH2)m(C R13R14)l (OCH2CH2)nO(C R13R14)l(CH2)m(C R13R14)l SZ, -CONR12(C R13R14)l(CH2)m(C R13R14)l(OCH2CH2)nO(C R13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)lSZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)lSZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)lSZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)nOCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)nNR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)nOCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)nOCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)nNR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)t(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO-morpholino-X(OCH2CH2)n SZ, -CO-piperazino-X(OCH2CH2)n SZ, -CO-piperidino-X(OCH2CH2)n SZ, and -CO-N-methylpiperazino-X(OCH2CH2)n SZ, wherein Z is H or SR, X is a linear alkyl or branched alkyl having 1-10 carbon atoms, R and R12 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms or heterocyclic, and R12 can in addition be H, R13 and R14 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or aryl, l is 0 or an integer from 1 to 10, m is an integer of 1 to 10, and n is 2 to 1000.
8. A compound of formula (I):
wherein:
R1 is H, an electron withdrawing group, or an electron donating group;
42~
R1' and R1" are the same or different and are H, an electron withdrawing group, or an electron donating group;
R2 is -(CR13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(C R13R14)l SZ, -CO(C R13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(C R13R14)l SZ, -CONR12(C R13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO-morpholino-X(OCH2CH2)n SZ, -CO-piperazino-X(OCH2CH2)n SZ, -CO-piperidino-X(OCH2CH2)n SZ, and -CO-N-methylpiperazino-X(OCH2CH2)n SZ, wherein Z is H or SR, X is a linear alkyl or branched alkyl having 1-10 carbon atoms, R and R12 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms or heterocyclic, and R12 can in addition be H, R13 and R14 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or aryl, 1 is 0 or an integer from 1 to 10, m is an integer of 1 to 10, and n is 2 to 1000;
R3 is aryl, or is linear, branched or cyclic alkyl having 1 to 10 carbon atoms;
R4 is -OC(CH3)3 or -C6H5; and R5 is H, a heterocyclic, a linear, branched, or cyclic ester or ether having from 1 to 10 carbon atoms or a carbamate of formula -CNR10R11, wherein R10 and R11 are the same or different and are H, linear, branched, or cyclic alkyl having 1 to 10 atoms or simple or substituted aryl having 1 to 10 carbon atoms.
wherein:
R1 is H, an electron withdrawing group, or an electron donating group;
42~
R1' and R1" are the same or different and are H, an electron withdrawing group, or an electron donating group;
R2 is -(CR13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(C R13R14)l SZ, -CO(C R13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(C R13R14)l SZ, -CONR12(C R13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO-morpholino-X(OCH2CH2)n SZ, -CO-piperazino-X(OCH2CH2)n SZ, -CO-piperidino-X(OCH2CH2)n SZ, and -CO-N-methylpiperazino-X(OCH2CH2)n SZ, wherein Z is H or SR, X is a linear alkyl or branched alkyl having 1-10 carbon atoms, R and R12 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms or heterocyclic, and R12 can in addition be H, R13 and R14 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or aryl, 1 is 0 or an integer from 1 to 10, m is an integer of 1 to 10, and n is 2 to 1000;
R3 is aryl, or is linear, branched or cyclic alkyl having 1 to 10 carbon atoms;
R4 is -OC(CH3)3 or -C6H5; and R5 is H, a heterocyclic, a linear, branched, or cyclic ester or ether having from 1 to 10 carbon atoms or a carbamate of formula -CNR10R11, wherein R10 and R11 are the same or different and are H, linear, branched, or cyclic alkyl having 1 to 10 atoms or simple or substituted aryl having 1 to 10 carbon atoms.
9. A compound of formula (I):
wherein:
R1 is H, an electron withdrawing group, or an electron donating group;
R1' and R1" are the same or different and are H, an electron withdrawing group, or an electron donating group;
R2 is H, a heterocyclic, a linear, branched, or cyclic ester or ether having from 1 to 10 carbon atoms or a carbamate of the formula -CNR10R11, wherein R10 and R11 are the same or different and are H, linear, branched, or cyclic alkyl having 1 to 10 atoms or simple or substituted aryl having 1 to 10 carbon atoms;
R3 is aryl, or is linear, branched or cyclic alkyl having 1 to 10 carbon atoms;
R4 is -OC(CH3)3 or -C6H5; and R5 is -(CR13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(C R13R14)l SZ, -CO(C R13R14)OCH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(C R13R14)l SZ, -CONR12(C R13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)t(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO-morpholino-X(OCH2CH2)n SZ, -CO-piperazino-X(OCH2CH2)n SZ, -CO-piperidino-X(OCH2CH2)n SZ, and -CO-N-methylpiperazino-X(OCH2CH2)n SZ, wherein Z is H or SR, X is a linear alkyl or branched alkyl having 1-10 carbon atoms, R and R12 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to
wherein:
R1 is H, an electron withdrawing group, or an electron donating group;
R1' and R1" are the same or different and are H, an electron withdrawing group, or an electron donating group;
R2 is H, a heterocyclic, a linear, branched, or cyclic ester or ether having from 1 to 10 carbon atoms or a carbamate of the formula -CNR10R11, wherein R10 and R11 are the same or different and are H, linear, branched, or cyclic alkyl having 1 to 10 atoms or simple or substituted aryl having 1 to 10 carbon atoms;
R3 is aryl, or is linear, branched or cyclic alkyl having 1 to 10 carbon atoms;
R4 is -OC(CH3)3 or -C6H5; and R5 is -(CR13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(C R13R14)l SZ, -CO(C R13R14)OCH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(C R13R14)l SZ, -CONR12(C R13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)t(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO-morpholino-X(OCH2CH2)n SZ, -CO-piperazino-X(OCH2CH2)n SZ, -CO-piperidino-X(OCH2CH2)n SZ, and -CO-N-methylpiperazino-X(OCH2CH2)n SZ, wherein Z is H or SR, X is a linear alkyl or branched alkyl having 1-10 carbon atoms, R and R12 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to
10 carbon atoms or heterocyclic, and R12 can in addition be H, R13 and R14 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or aryl, 1 is 0 or an integer from 1 to 10, m is an integer of 1 to 10, and n is 2 to 1000.
10. The compound of claim 8 or 9, wherein R1 is H, F, NO2, CN, Cl, CHF2, CF3, -OCH3, -OCH2CH3, -NR6R7, or -OR8.
10. The compound of claim 8 or 9, wherein R1 is H, F, NO2, CN, Cl, CHF2, CF3, -OCH3, -OCH2CH3, -NR6R7, or -OR8.
11. The compound of claim 8 or 9, wherein R1 is OMe, OEt, Cl, F, NO2, or CF3.
12. The compound of claim 8 or 9, wherein R1 is in the meta position, R1' is OMe, and R1" is H.
13. The compound of claim 8 or 9, wherein R1' and R1" are the same or different and are H, F, NO2, CN, Cl, CHF2, CF3, -OCH3, OCH2CH3, -NR6R7, or -OR8, wherein:
R6 and R7 are the same or different and are each H, linear, branched, or cyclic alkyl groups having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms, and R8 is linear, branched or cyclic alkyl having 1 to 10 carbon atoms.
R6 and R7 are the same or different and are each H, linear, branched, or cyclic alkyl groups having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms, and R8 is linear, branched or cyclic alkyl having 1 to 10 carbon atoms.
14. The compound of claim 13, wherein R6 and R7 are same or different and are each H, or are alkyl or aryl having 1 to 4 carbon atoms.
15. The compound of claim 13, wherein -NR6R7 is dimethyl amino, diethyl amino, dipropyl amino, or dibutyl amino, where the butyl moiety is any of primary, secondary, tertiary or isobutyl..
16. The compound of claim 8 or 9, wherein R3 is -CH2CH(CH3)2 or -CH=C(CH3)2.
17. The compound of claim 8 or 9, wherein R4 is -OC(CH3)3 or -C6H5.
18. The compound of claim 8, wherein R5 is H, -COCH3, -COCH2CH3 and -COCH2CH2CH3.
19. The compound of claim 9, wherein R2 is H, -COCH3, -COCH2CH3 and -COCH2CH2CH3.
20. The compound of claim 8, wherein R5 is H, or -CONHCH2CH3, -CONHCH2CH2CH3, -CO-morpholino, -CO-piperazino, -CO-piperidino, or -CO-N-methylpiperazino.
21. The compound of claim 9, wherein R2 is H, or -CONHCH2CH3, -CONHCH2CH2CH3, -CO-morpholino, -CO-piperazino, -CO-piperidino, or -CO-N-methylpiperazino.
22. A cytotoxic agent comprising one or more taxanes linked to a cell binding agent through a polyethylene glycol-containing linking group at C-7 or C-10 of at least one of the taxanes.
23. The cytotoxic agent of claim 22, wherein the polyethylene glycol-containing linking group comprises a thiol or disulfide as the linking moiety.
24. The cytotoxic agent of claim 22, wherein the polyethylene glycol-containing linking group is carried on a side chain that is a linear or branched, aromatic or heterocyclic group.
25. The cytotoxic agent of claim 22, wherein at least one of the taxanes is linked to the cell binding agent through a cleavable linking group.
26. The cytotoxic agent of claim 25, wherein the cleavable linking group is acid labile, photolabile, peptidase labile or esterase labile.
27. The cytotoxic agent of claim 22, wherein at least one of the taxanes is linked to the cell binding agent through a non-cleavable linking group.
28. The cytotoxic agent of claim 22, wherein the substituent comprising the polyethylene glycol-containing linking group is selected from the group consisting of:
-(CR13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(C R13R14)l SZ, -CO(C R13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(C R13R14)l SZ, -CONR12(C R13R14)l(CH1)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO-morpholino-X(OCH2CH2)n SZ, -CO-piperazino-X(OCH2CH2)n SZ, -CO-piperidino-X(OCH2CH2)n SZ, and -CO-N-methylpiperazino-X(OCH2CH2)n SZ, wherein Z is H or SR, X is a linear alkyl or branched alkyl having 1-10 carbon atoms, R and R12 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms or heterocyclic, and R12 can in addition be H, R13 and R14 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or aryl, l is 0 or an integer from 1 to 10, m is an integer of 1 to 10, and n is 2 to 1000.
-(CR13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(C R13R14)l SZ, -CO(C R13R14)l(CH2)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(C R13R14)l SZ, -CONR12(C R13R14)l(CH1)m(C R13R14)l(OCH2CH2)n O(C R13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO-morpholino-X(OCH2CH2)n SZ, -CO-piperazino-X(OCH2CH2)n SZ, -CO-piperidino-X(OCH2CH2)n SZ, and -CO-N-methylpiperazino-X(OCH2CH2)n SZ, wherein Z is H or SR, X is a linear alkyl or branched alkyl having 1-10 carbon atoms, R and R12 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms or heterocyclic, and R12 can in addition be H, R13 and R14 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or aryl, l is 0 or an integer from 1 to 10, m is an integer of 1 to 10, and n is 2 to 1000.
29. The cytotoxic agent of claim 22, wherein the cell binding agent is an antibody or an antibody fragment.
30. The cytotoxic agent of claim 22, wherein the cell binding agent is an antibody, a single chain antibody or a binding fragment of an antibody or single chain antibody.
31. The cytotoxic agent of claim 22, wherein the cell binding agent is a monoclonal antibody, a single chain monoclonal antibody or a binding fragment of a single chain monoclonal antibody a monoclonal antibody which is or is not humanized or resurfaced or chimeric.
32. The cytotoxic agent of claim 31, wherein the cell binding agent binds specifically to the CD33 antigen.
33. The cytotoxic agent of claim 31, wherein the cell binding agent binds specially to the CD56 antigen.
34. The cytotoxic agent of claim 22, wherein the cell binding agent is an interferon, a lymphokine, a hormone, a vitamin, a growth factor, a colony-stimulating factor, or transferrin.
35. The cytotoxic agent of claim 22, wherein the cell binding agent is epidermal growth factor, transforming growth factor, vascular endothelial growth factor, fibroblast growth factor, insulin like growth factor 1 and 2, platelet derived growth factor, melanocyte stimulating hormone, thyroid stimulating hormone, somatostatin, estrogen, estrogen analogue, androgen, androgen analogue, or folate.
36. A therapeutic composition comprising:
(A) An effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent through a polyethylene glycol-containing linking group at C-7 or C-10 of at least one of the taxanes; and (B) A pharmaceutically acceptable carrier, diluent, or excipient.
(A) An effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent through a polyethylene glycol-containing linking group at C-7 or C-10 of at least one of the taxanes; and (B) A pharmaceutically acceptable carrier, diluent, or excipient.
37. The therapeutic composition of claim 36, wherein the polyethylene glycol-containing linking group comprises a thiol or disulfide as the linking moiety.
38. The therapeutic composition of claim 36, wherein the polyethylene glycol-containing linking group is carried on a side chain that is a linear or branched, aromatic or heterocyclic group.
39. The therapeutic composition of claim 36, wherein at least one of the taxanes is linked to the cell binding agent through a cleavable linking group.
40. The therapeutic composition of claim 39, wherein the cleavable linking group is acid labile, photolabile, peptidase labile or esterase labile.
41. The therapeutic composition of claim 36, wherein at least one of the taxanes is linked to the cell binding agent through a non-cleavable linking group.
42. The therapeutic composition of claim 36, wherein the substituent comprising the polyethylene glycol-containing linking group is selected from the group consisting of:
-(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n O(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n O(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n O(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ
-CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO-morpholino-X(OCH2CH2)n SZ, -CO-piperazino-X(OCH2CH2)n SZ, -CO-piperidino-X(OCH2CH2)n SZ, and -CO-N-methylpiperazino-X(OCH2CH2)n SZ, wherein Z is H or SR, X is a linear alkyl or branched alkyl having 1-10 carbon atoms, R and R12 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms or heterocyclic, and R12 can in addition be H, R13 and R14 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or aryl, l is 0 or an integer from 1 to 10, m is an integer of 1 to 10, and n is 2 to 1000.
-(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n O(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n O(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n O(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CO(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCO(CR13R14)l(CH2)m(CR13R14)l SZ
-CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n NR12CO(CR13R14)l(CH2)m(CR13R14)l SZ, -CONR12(CR13R14)l(CH2)m(CR13R14)l(OCH2CH2)n OCONR12(CR13R14)l(CH2)m(CR13R14)l SZ, -CO-morpholino-X(OCH2CH2)n SZ, -CO-piperazino-X(OCH2CH2)n SZ, -CO-piperidino-X(OCH2CH2)n SZ, and -CO-N-methylpiperazino-X(OCH2CH2)n SZ, wherein Z is H or SR, X is a linear alkyl or branched alkyl having 1-10 carbon atoms, R and R12 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms or heterocyclic, and R12 can in addition be H, R13 and R14 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or aryl, l is 0 or an integer from 1 to 10, m is an integer of 1 to 10, and n is 2 to 1000.
43. The therapeutic composition of claim 36 or 37, wherein the cell binding agent is an antibody or an antibody fragment.
44. The therapeutic composition of any one of claims 36, 37, 38 or 42, wherein the cell binding agent is an antibody, a single chain antibody or a binding fragment of an antibody or single chain antibody.
45. The therapeutic composition of any one of claims 36, 37, 38 or 42, wherein the cell binding agent is a monoclonal antibody, a single chain monoclonal antibody or a binding fragment of a single chain monoclonal antibody a monoclonal antibody which is or is not humanized or resurfaced or chimeric?.
46. The therapeutic composition of claim 45, wherein the cell binding agent binds specifically to the CD33 antigen.
47. The therapeutic composition of claim 45, wherein the cell binding agent binds specifically to the CD 19 antigen.
48. The therapeutic composition of any one of claims 36, 37, 38 or 42, wherein the cell binding agent is an interferon, a lymphokine, a hormone, a vitamin, a growth factor, a colony-stimulating factor, or transferrin.
49. The therapeutic composition of any one of claims 36, 37, 38 or 42, wherein the cell binding agent is epidermal growth factor, , transforming growth factor, vascular endothelial growth factor, fibroblast growth factor, insulin like growth factor 1 and 2, platelet derived growth factor, somatostatin, melanocyte stimulating hormone, thyroid stimulating hormone, estrogen, estrogen analogue, androgen, androgen analogue, or folate.
50. A method of killing selected cell populations comprising contacting target cells or tissue containing target cells with a cytotoxic amount of the cytotoxic agent of any one of claims 22 to 35.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/144,042 US6596757B1 (en) | 2002-05-14 | 2002-05-14 | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
US10/144,042 | 2002-05-14 | ||
PCT/US2003/002675 WO2003097625A1 (en) | 2002-05-14 | 2003-02-11 | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2485424A1 true CA2485424A1 (en) | 2003-11-27 |
CA2485424C CA2485424C (en) | 2010-12-14 |
Family
ID=22506806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2485424A Expired - Fee Related CA2485424C (en) | 2002-05-14 | 2003-02-11 | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
Country Status (6)
Country | Link |
---|---|
US (1) | US6596757B1 (en) |
EP (1) | EP1506181A4 (en) |
JP (2) | JP2005533026A (en) |
AU (1) | AU2003210731C1 (en) |
CA (1) | CA2485424C (en) |
WO (1) | WO2003097625A1 (en) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4808846B2 (en) * | 1999-02-24 | 2011-11-02 | ザ ユーエイビー リサーチ ファンデイション | Taxane derivatives for targeted treatment of cancer |
EP1389209B1 (en) * | 2001-04-24 | 2009-04-08 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
EP2335728A1 (en) | 2001-05-11 | 2011-06-22 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
DE60326833D1 (en) * | 2002-05-15 | 2009-05-07 | Endocyte Inc | VITAMIN MITOMYCIN CONJUGATES |
AU2003247587B2 (en) * | 2002-08-02 | 2009-07-09 | Immunogen, Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
US7390898B2 (en) * | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
AR042942A1 (en) * | 2003-01-27 | 2005-07-06 | Endocyte Inc | CONJUGATES OF DRUG ADMINISTRATION OF VITAMIN RECEPTORS UNION |
KR101424624B1 (en) | 2003-05-14 | 2014-07-31 | 이뮤노젠 아이엔씨 | Drug Conjugate Composition |
US7834155B2 (en) | 2003-07-21 | 2010-11-16 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
WO2005079861A2 (en) * | 2004-02-13 | 2005-09-01 | Safeway Investments Ltd. | Polymeric water soluble prodrugs |
US8288557B2 (en) * | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
AU2004224925C1 (en) * | 2004-08-30 | 2011-07-21 | Biotest Ag | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
US20080113028A1 (en) * | 2004-09-22 | 2008-05-15 | Kazuhisa Shimizu | Novel Block Copolymer, Micelle Preparation, And Anticancer Agent Containing The Same As Active Ingredient |
EP1688415A1 (en) * | 2004-12-07 | 2006-08-09 | Aventis Pharma S.A. | Cytotoxic agents comprising new C-2 modified taxanes |
EP1669358A1 (en) * | 2004-12-07 | 2006-06-14 | Aventis Pharma S.A. | Cytotoxic agents comprising new taxanes |
US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
CA2597407C (en) | 2005-02-11 | 2013-09-10 | Immunogen, Inc. | Process for preparing stable drug conjugates |
US8044200B2 (en) * | 2005-03-16 | 2011-10-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
EA014513B1 (en) | 2005-08-03 | 2010-12-30 | Иммьюноджен, Инк. | Immunoconjugate formulations |
JP2009504783A (en) * | 2005-08-19 | 2009-02-05 | エンドサイト,インコーポレイテッド | Ligand conjugates of vinca alkaloids, analogues and derivatives |
KR20130113543A (en) | 2005-08-19 | 2013-10-15 | 엔도사이트, 인코포레이티드 | Multi-drug ligand conjugates |
RS52470B (en) | 2005-08-24 | 2013-02-28 | Immunogen Inc. | Process for preparing maytansinoid antibody conjugates |
EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
KR20080106254A (en) * | 2006-03-28 | 2008-12-04 | 니폰 가야꾸 가부시끼가이샤 | Polymer conjugate of taxane |
EP2019122A4 (en) | 2006-05-18 | 2009-07-01 | Nippon Kayaku Kk | Polymer conjugate of podophyllotoxin |
JP5622390B2 (en) | 2006-07-18 | 2014-11-12 | サノフイ | Anti-EPHA2 antagonist antibody for cancer treatment |
WO2008041610A1 (en) * | 2006-10-03 | 2008-04-10 | Nippon Kayaku Kabushiki Kaisha | Compound of resorcinol derivative with polymer |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
WO2008056596A1 (en) | 2006-11-06 | 2008-05-15 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
JP5548365B2 (en) | 2006-11-08 | 2014-07-16 | 日本化薬株式会社 | Polymer derivatives of nucleic acid antimetabolites |
CN104043123B (en) | 2007-01-25 | 2019-08-13 | 达娜-法勃肿瘤研究所公司 | Purposes of the anti-egfr antibodies in the mutant mediated disease for the treatment of EGFR |
WO2008101231A2 (en) * | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
EP2481427A1 (en) * | 2007-03-14 | 2012-08-01 | Endocyte, Inc. | Folate-Tubulysin conjugates |
AU2008227123B2 (en) | 2007-03-15 | 2014-03-27 | Ludwig Institute For Cancer Research Ltd. | Treatment method using EGFR antibodies and src inhibitors and related formulations |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
RU2523909C2 (en) | 2007-06-25 | 2014-07-27 | Эндосайт, Инк. | Conjugates, containing hydrophilic spacers of linkers |
PE20120259A1 (en) | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | ANTI-CD37 ANTIBODIES |
MX2010001757A (en) | 2007-08-14 | 2010-09-14 | Ludwig Inst Cancer Res | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof. |
JP5349318B2 (en) | 2007-09-28 | 2013-11-20 | 日本化薬株式会社 | Steroids polymer conjugates |
AU2008316835B2 (en) | 2007-10-25 | 2015-07-16 | Endocyte, Inc. | Tubulysins and processes for preparing |
RU2547939C2 (en) * | 2007-12-26 | 2015-04-10 | Биотест Аг | Anti-cd138 immunoconjugates and using them |
MX341344B (en) | 2007-12-26 | 2016-08-16 | Biotest Ag | Agents targeting cd138 and uses thereof. |
JP2011508738A (en) * | 2007-12-26 | 2011-03-17 | バイオテスト・アクチエンゲゼルシヤフト | Method and agent for improving targeting of CD138 expressing tumor cells |
WO2009080831A1 (en) * | 2007-12-26 | 2009-07-02 | Biotest Ag | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
CN101977631A (en) * | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | Polymer conjugate of physiologically active substance |
RU2487877C2 (en) * | 2008-04-30 | 2013-07-20 | Иммьюноджен, Инк. | Potent conjugates and hydrophilic cross-linking agents (linkers) |
JP5769616B2 (en) | 2008-04-30 | 2015-08-26 | イミュノジェン・インコーポレーテッド | Crosslinkers and their use |
EP2284209B1 (en) | 2008-05-08 | 2016-08-31 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
JP5544357B2 (en) | 2009-05-15 | 2014-07-09 | 日本化薬株式会社 | Polymer conjugate of a physiologically active substance having a hydroxyl group |
SG10201810743WA (en) | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
AU2010292172A1 (en) * | 2009-09-09 | 2012-05-03 | Centrose, Llc | Extracellular targeted drug conjugates |
IN2012DN02780A (en) | 2009-10-06 | 2015-09-18 | Immunogen Inc | |
RU2573994C2 (en) | 2010-02-10 | 2016-01-27 | Иммьюноджен, Инк | Anti-cd20 antibodies and thereof application |
NZ705128A (en) | 2010-03-04 | 2015-04-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
WO2012067138A1 (en) | 2010-11-17 | 2012-05-24 | 日本化薬株式会社 | Novel polymer derivative of cytidine metabolism antagonist |
WO2012066581A1 (en) * | 2010-11-19 | 2012-05-24 | Venus Remedies Limited | Novel conjugates for targeted drug delivery |
EA201991268A3 (en) | 2011-03-29 | 2020-01-31 | Иммуноджен, Инк. | OBTAINING MAYTANSINOID-ANTIBODIES CONJUGATES IN ONE-STEP METHOD |
WO2012135517A2 (en) | 2011-03-29 | 2012-10-04 | Immunogen, Inc. | Preparation of maytansinoid antibody conjugates by a one-step process |
EP2714733B1 (en) | 2011-05-21 | 2019-01-23 | MacroGenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
TWI597065B (en) | 2011-06-10 | 2017-09-01 | 梅爾莎納醫療公司 | Protein-polymer-drug conjugates |
WO2013035641A1 (en) | 2011-09-11 | 2013-03-14 | 日本化薬株式会社 | Method for manufacturing block copolymer |
ES2684950T3 (en) | 2011-12-08 | 2018-10-05 | Biotest Ag | Uses of immunoconjugates directed to CD138 |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
EP2841099A1 (en) | 2012-04-26 | 2015-03-04 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with bendamustine |
WO2013171289A1 (en) | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with further agents |
EP2849784A1 (en) | 2012-05-16 | 2015-03-25 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
NZ707091A (en) | 2012-10-04 | 2018-12-21 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
CA2887727A1 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
ES2701076T3 (en) | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells |
US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
WO2014093394A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
EP2931316B1 (en) | 2012-12-12 | 2019-02-20 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
WO2015054659A1 (en) | 2013-10-11 | 2015-04-16 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2015054669A1 (en) | 2013-10-11 | 2015-04-16 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
JP6533534B2 (en) | 2014-02-14 | 2019-06-19 | マクロジェニクス,インコーポレーテッド | Composition for use in the treatment of glioblastoma and use thereof |
CN114262344A (en) | 2014-02-28 | 2022-04-01 | 杭州多禧生物科技有限公司 | Charged linkers and their use in conjugation reactions |
NZ739830A (en) | 2015-07-12 | 2021-12-24 | Hangzhou Dac Biotech Co Ltd | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
US10509035B2 (en) | 2015-08-07 | 2019-12-17 | Gamamabs Pharma Sa | Antibodies, antibody drug conjugates and methods of use |
TW201808336A (en) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | Treatment regimen using anti-MUC1 maytansinoid immunoconjugate antibody for the treatment of tumors |
KR20220147721A (en) | 2016-11-14 | 2022-11-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
TW201905037A (en) | 2017-06-22 | 2019-02-01 | 美商梅爾莎納醫療公司 | Drug-carrying polymer scaffold and method for producing protein polymer drug conjugate |
EP3755718A1 (en) | 2018-02-21 | 2020-12-30 | Celgene Corporation | Bcma-binding antibodies and uses thereof |
EP3873534A1 (en) | 2018-10-29 | 2021-09-08 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
US11786605B2 (en) | 2020-01-09 | 2023-10-17 | Mersana Therapeutics, Inc. | Site specific antibody-drug conjugates with peptide-containing linkers |
US20230256114A1 (en) | 2020-07-07 | 2023-08-17 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
EP3970752A1 (en) | 2020-09-17 | 2022-03-23 | Merck Patent GmbH | Molecules with solubility tag and related methods |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993024476A1 (en) * | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
US5547981A (en) * | 1993-03-09 | 1996-08-20 | Enzon, Inc. | Taxol-7-carbazates |
US5824701A (en) * | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
JP4808846B2 (en) * | 1999-02-24 | 2011-11-02 | ザ ユーエイビー リサーチ ファンデイション | Taxane derivatives for targeted treatment of cancer |
DK1242401T3 (en) * | 1999-11-24 | 2007-05-07 | Immunogen Inc | Cytotoxic agents comprising taxanes and their therapeutic use |
EP1279405A1 (en) * | 2000-03-30 | 2003-01-29 | Ajinomoto Co., Inc. | Drugs retained in target tissue over long time |
-
2002
- 2002-05-14 US US10/144,042 patent/US6596757B1/en not_active Expired - Fee Related
-
2003
- 2003-02-11 WO PCT/US2003/002675 patent/WO2003097625A1/en active Application Filing
- 2003-02-11 AU AU2003210731A patent/AU2003210731C1/en not_active Ceased
- 2003-02-11 CA CA2485424A patent/CA2485424C/en not_active Expired - Fee Related
- 2003-02-11 EP EP03752980A patent/EP1506181A4/en not_active Withdrawn
- 2003-02-11 JP JP2004505358A patent/JP2005533026A/en active Pending
-
2010
- 2010-10-25 JP JP2010238562A patent/JP2011042679A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1506181A4 (en) | 2006-11-08 |
AU2003210731C1 (en) | 2009-11-05 |
CA2485424C (en) | 2010-12-14 |
US6596757B1 (en) | 2003-07-22 |
EP1506181A1 (en) | 2005-02-16 |
AU2003210731B2 (en) | 2009-06-11 |
AU2003210731A1 (en) | 2003-12-02 |
JP2005533026A (en) | 2005-11-04 |
AU2003210731B8 (en) | 2009-06-25 |
JP2011042679A (en) | 2011-03-03 |
WO2003097625A1 (en) | 2003-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2485424A1 (en) | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use | |
CA2388063A1 (en) | Cytotoxic agents comprising taxanes and their therapeutic use | |
JP2005533026A5 (en) | ||
JP2003514903A5 (en) | ||
KR960701045A (en) | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | |
RU2011136686A (en) | NEW DERIVATIVES OF BENZODIAZEPINE | |
HUP0202572A2 (en) | Organic silicon compounds | |
ATE294592T1 (en) | CONJUGATES CONTAINING THIOETHER | |
RU2009102243A (en) | CAMPTOTECINE DERIVATIVES WITH ANTITUMOR ACTIVITY | |
RU2000128058A (en) | ECTEINASCIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND METHOD FOR TREATING TUMORS | |
EP1484058A3 (en) | Pharmaceutical composition for inhibiting altering gene expression and for inducing differentiation in non-malignant cells | |
CA2321149A1 (en) | Antitumor agents | |
CA2441398A1 (en) | Lipid lowering biphenylcarboxamides | |
WO2001026629A3 (en) | Neutral-cationic lipid for nucleic acid and drug delivery | |
AU581324B2 (en) | Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones | |
RU2008111492A (en) | COMBINATIONS (COMPOSITIONS) INCLUDING DMXAA FOR TREATMENT OF CANCER | |
JP2019507126A5 (en) | ||
CA2395980A1 (en) | 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase i inhibition | |
YU46699A (en) | Improved method for producing thiazolidinediones, and new thiazolidinediones | |
WO2003022844A3 (en) | Synthesis of epothilones intermediates thereto and analogues thereof | |
WO2005007079A3 (en) | Inactivators and bivalent inhibitors of glyoxalase i and methods of inhibiting tumor growth | |
DE60201903D1 (en) | IRON POWDER COMPOSITION WITH AN AMID LUBRICANT AND METHOD FOR THE PRODUCTION THEREOF | |
KR960703623A (en) | Improvements to Pro Drugs (lmprovements relating to prodrugs) | |
CA2432027A1 (en) | Novel bifunctional chelating compounds containing hydroxamic acid residues | |
AR002249A1 (en) | A COMPOUND OF OXAZOLE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT, A PROCESS FOR THE PREPARATION OF THE SAME AND AN INTERMEDIATE COMPOUND FOR SUCH A PROCESS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20130211 |